Literature DB >> 11093799

Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains.

Z Lin1, W Wang, G R Uhl.   

Abstract

Cocaine blocks the normal role of the dopamine transporter (DAT) in terminating dopamine signaling and in restricting its spatial spread through molecular interactions that remain largely obscure. Cocaine analog structure-activity studies suggest roles for cationic and hydrophobic interactions between DAT, dopamine, cocaine, and the sodium and chloride ions whose gradients power uptake processes. Tryptophan residues lying in putative DAT transmembrane domains could contribute to both aromatic and cationic interactions between DAT and dopamine or cocaine. We thus produced mutant DATs with alanine substitutions for tryptophans lying in or near putative DAT transmembrane domains. We have focused analyses on mutations that exert selective influences on affinities for dopamine or the cocaine analog CFT [(-)-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane]. Substitutions W162A, W255A, and W310A reduced dopamine uptake affinities. 5W266A, 12W555A, and 12W561A each reduced dopamine superficial recognition affinities by more than 3-fold and all retained affinity for CFT. W406A, W496A and W523A each reduced CFT affinity, and W84A increased CFT affinity. None of these four mutations decreased dopamine uptake affinity. These data, current provisional DAT structural models, and results from parallel studies of other mutants identify candidate dopamine-selective DAT domains for transmembrane dopamine permeation and regions in which mutations selectively lower CFT affinities. Tryptophan residues may contribute more extensively to these selective domains than other previously studied DAT amino acids. These sites provide tempting targets for selective blockers of cocaine recognition by DAT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093799     DOI: 10.1124/mol.58.6.1581

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

Review 1.  Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6.

Authors:  Nian-Hang Chen; Maarten E A Reith; Michael W Quick
Journal:  Pflugers Arch       Date:  2003-04-29       Impact factor: 3.657

2.  Synthesis, in vitro binding studies and docking of long-chain arylpiperazine nitroquipazine analogues, as potential serotonin transporter inhibitors.

Authors:  Małgorzata Jarończyk; Karol Wołosewicz; Mari Gabrielsen; Gabriel Nowak; Irina Kufareva; Aleksander P Mazurek; Aina W Ravna; Ruben Abagyan; Andrzej J Bojarski; Ingebrigt Sylte; Zdzisław Chilmonczyk
Journal:  Eur J Med Chem       Date:  2012-01-15       Impact factor: 6.514

Review 3.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

Review 4.  Trafficking of dopamine transporters in psychostimulant actions.

Authors:  Nancy R Zahniser; Alexander Sorkin
Journal:  Semin Cell Dev Biol       Date:  2009-01-22       Impact factor: 7.727

5.  Structure and localisation of drug binding sites on neurotransmitter transporters.

Authors:  Aina W Ravna; Ingebrigt Sylte; Svein G Dahl
Journal:  J Mol Model       Date:  2009-02-24       Impact factor: 1.810

6.  Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.

Authors:  Kyle C Schmitt; Juan Zhen; Prashant Kharkar; Manoj Mishra; Nianhang Chen; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurochem       Date:  2008-09-11       Impact factor: 5.372

7.  Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate-binding site.

Authors:  Rejwi Acharya Dahal; Akula Bala Pramod; Babita Sharma; Danielle Krout; James D Foster; Joo Hwan Cha; Jianjing Cao; Amy Hauck Newman; John R Lever; Roxanne A Vaughan; L Keith Henry
Journal:  J Biol Chem       Date:  2014-08-31       Impact factor: 5.157

8.  The LeuT-fold neurotransmitter:sodium symporter MhsT has two substrate sites.

Authors:  Matthias Quick; Ara M Abramyan; Pattama Wiriyasermkul; Harel Weinstein; Lei Shi; Jonathan A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-06       Impact factor: 11.205

9.  Antagonist-induced conformational changes in dopamine transporter extracellular loop two involve residues in a potential salt bridge.

Authors:  Jon D Gaffaney; Madhur Shetty; Bruce Felts; Akula-Bala Pramod; James D Foster; L Keith Henry; Roxanne A Vaughan
Journal:  Neurochem Int       Date:  2013-11-20       Impact factor: 3.921

10.  A mechanism for intracellular release of Na+ by neurotransmitter/sodium symporters.

Authors:  Lina Malinauskaite; Matthias Quick; Linda Reinhard; Joseph A Lyons; Hideaki Yano; Jonathan A Javitch; Poul Nissen
Journal:  Nat Struct Mol Biol       Date:  2014-10-05       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.